|
ELOVL6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.11022302462516E-16 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62547753035369E-12 |
| Normal-vs-Stage2 |
4.336700E-03 |
| Normal-vs-Stage3 |
2.83600032346953E-10 |
| Normal-vs-Stage4 |
2.47870000003036E-06 |
| Stage1-vs-Stage2 |
1.830290E-02 |
| Stage1-vs-Stage3 |
9.610800E-01 |
| Stage1-vs-Stage4 |
6.058400E-01 |
| Stage2-vs-Stage3 |
4.133700E-02 |
| Stage2-vs-Stage4 |
3.078100E-02 |
| Stage3-vs-Stage4 |
6.295200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62458935193399E-12 |
| Normal-vs-AfricanAmerican |
8.0010999999991E-05 |
| Normal-vs-Asian |
1.186920E-04 |
| Caucasian-vs-AfricanAmerican |
7.960000E-01 |
| Caucasian-vs-Asian |
2.216200E-03 |
| AfricanAmerican-vs-Asian |
3.992500E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.3901000067994E-09 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
1.343790E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.18689502670577E-11 |
| Normal-vs-Age(41-60Yrs) |
1.6796564139554E-12 |
| Normal-vs-Age(61-80Yrs) |
3.56170000048728E-07 |
| Normal-vs-Age(81-100Yrs) |
3.025600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.190050E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.262560E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.660200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.813600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.740600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.021000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.214600E-01 |
| Classical-VS-Follicular |
6.592700E-04 |
| Classical-VS-Other |
7.609800E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.297830E-02 |
| Tall-VS-Other |
5.918000E-01 |
| Tall-VS-Normal |
3.63180000000352E-05 |
| Follicular-VS-Other |
4.015800E-01 |
| Follicular-VS-Normal |
4.180400E-03 |
| Other-VS-Normal |
8.113800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.82910353530019E-11 |
| Normal-vs-N1 |
1.22150000003707E-06 |
| N0-vs-N1 |
2.657200E-01 |
|
|
